Pratt Catherine G, Whitrock Jenna N, Shah Shimul A, Fong Zhi Ven
Cincinnati Research in Outcomes and Safety in Surgery (CROSS) Research Group, Department of Surgery, University of Cincinnati College of Medicine, 231 Albert Sabin Way, ML 0558, Cincinnati, OH 45267-0558, USA. Electronic address: https://twitter.com/CPrattMD.
Cincinnati Research in Outcomes and Safety in Surgery (CROSS) Research Group, Department of Surgery, University of Cincinnati College of Medicine, 231 Albert Sabin Way, ML 0558, Cincinnati, OH 45267-0558, USA. Electronic address: https://twitter.com/JennaWhitrockMD.
Surg Clin North Am. 2024 Feb;104(1):197-214. doi: 10.1016/j.suc.2023.09.001. Epub 2023 Sep 27.
Hilar cholangiocarcinoma is considered a biologically aggressive disease for which surgical resection remains the only curative treatment. Preoperative evaluation for resectability is challenging given tumor proximity to the porta hepatis, but minimal benefit and increased morbidity precludes recommendation for margin positive resection. This article reviews the determination of unresectability in hilar cholangiocarcinoma through discussion of the preoperative assessment, the intraoperative assessment, and key steps of surgical resection, as well as treatment options for unresectable tumors. Overall, evaluating patients preoperatively for resectability requires a multidisciplinary, holistic, and individualized approach to accurately determine resectability and optimize clinical outcomes for patients with hilar cholangiocarcinoma.
肝门部胆管癌被认为是一种具有生物学侵袭性的疾病,手术切除仍然是唯一的治愈性治疗方法。鉴于肿瘤靠近肝门,术前评估可切除性具有挑战性,但切缘阳性切除的获益极小且发病率增加,因此不推荐进行。本文通过讨论术前评估、术中评估、手术切除的关键步骤以及不可切除肿瘤的治疗选择,综述了肝门部胆管癌不可切除性的判定。总体而言,术前评估患者的可切除性需要采用多学科、全面且个体化的方法,以准确确定可切除性并优化肝门部胆管癌患者的临床结局。